Home | All trials

[RDF data]
Trial NCT00000329

Resource URI: http://static.linkedct.org/resource/trials/NCT00000329
PropertyValue
linkedct:brief_title Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment II-1 - 4
linkedct:collaborator_agency <http://static.linkedct.org/resource/collabagency/8711>
linkedct:condition <http://static.linkedct.org/resource/condition/5932>
linkedct:condition <http://static.linkedct.org/resource/condition/9249>
linkedct:criteria Inclusion Criteria: Individuals must be at least 18 yrs of age, currently opioid dependent and meet FDA critera for narcotic maintenance treatment. Co-morbid substance abuse or dependence disorders may also be present. Individuals must be healthy despite drug dependency and have a history of IV opioid use. Exclusion Criteria: Individuals with evidence of anti active DSM-IV Axis I psychiatric disorder (e.g. psychosis, manic-depressive illness, organic psychiatric disorders), significant medical illness (e.g. liver or cardiovascular disease) or pregnant female subjects are excluded from study participation.
linkedct:description Ongoing study - results not available at this time
linkedct:download_date Information obtained from ClinicalTrials.gov on December 30, 2009
linkedct:eligibility_gender Both
linkedct:eligibility_healthy_volunteers No
linkedct:eligibility_maximum_age 65 Years
linkedct:eligibility_minimum_age 18 Years
linkedct:enrollment 0 (xsd:int)
linkedct:firstreceived_date September 20, 1999
linkedct:id NCT00000329
rdfs:label Trial NCT00000329
linkedct:lastchanged_date November 3, 2005
linkedct:lead_sponsor_agency National Institute on Drug Abuse (NIDA)
linkedct:location <http://static.linkedct.org/resource/location/205451>
linkedct:nct_id NCT00000329
linkedct:number_of_arms 0 (xsd:int)
linkedct:number_of_groups 0 (xsd:int)
linkedct:official_title Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment II-1
linkedct:org_study_id NIDA-11160-4
linkedct:overall_official <http://static.linkedct.org/resource/overall_official/35001>
linkedct:overall_status Completed
linkedct:oversight <http://static.linkedct.org/resource/oversight/2918>
foaf:page <http://clinicaltrials.gov/show/NCT00000329>
linkedct:phase Phase 2
linkedct:primary_outcomes <http://static.linkedct.org/resource/primary_outcomes/14202>
linkedct:primary_outcomes <http://static.linkedct.org/resource/primary_outcomes/14372>
linkedct:primary_outcomes <http://static.linkedct.org/resource/primary_outcomes/14374>
linkedct:primary_outcomes <http://static.linkedct.org/resource/primary_outcomes/17569>
linkedct:primary_outcomes <http://static.linkedct.org/resource/primary_outcomes/1803>
linkedct:primary_outcomes <http://static.linkedct.org/resource/primary_outcomes/20857>
linkedct:primary_outcomes <http://static.linkedct.org/resource/primary_outcomes/7277>
linkedct:primary_outcomes <http://static.linkedct.org/resource/primary_outcomes/7298>
linkedct:secondary_id R01-11160-4
linkedct:source National Institute on Drug Abuse (NIDA)
linkedct:start_date April 1999
linkedct:study_design Treatment, Double-Blind, Placebo Control
linkedct:study_type Interventional
linkedct:summary The purpose of this study is to assess the abuse liability and examine the reinforcing effects of intravenous buprenorphine and buprenorphine/naloxone combinations in buprenorphine-naloxone maintained volunteers
rdf:type linkedct:trials
linkedct:verification_date April 1999